ArticlesPorsche Cayenne Turbo Electric has arrived in Bucharest
ArticlesCompetitive Benchmarking: How to Spot Gaps and Drive Smarter Growth
ArticlesDeloitte study: eight out of ten commercial real estate companies expect revenue growth in 2026
ArticlesTop 100 City Destinations Index 2025: Driving Growth and Innovation
ArticlesThe competitive advantage that transforms your business
InterviewsPUTTING ROMANIAN CORPORATE COMPANIES ON THE INTERNATIONAL BUSINESS SCENE
InterviewsOUR EDGE WILL COME FROM BEING THE MOST DIGITALIZED WHOLESALER IN ROMANIA
InterviewsCOFFEE IS OUR LOVE LANGUAGE
InterviewsBUILDING THE FUTURE OF ENERGY: ENEVO GROUP’S ONE-STOP-SHOP MODEL FOR THE ENERGY TRANSITION
InterviewsROOTED IN ROMANIA, BUILT TO DELIVER TECHNOLOGY FOR THE WORLD - EVANTAGE SOFT MODEL FOR GLOBAL IMPACT
NewsIntracom Telecom Showcases AI-Powered Wireless Fiber Solutions at MWC 2026
NewsThe New S-Class: Refinement, Innovation and 140 Years of History
NewsSchneider Electric to become the Official Energy Technology Partner of McLaren Racing
News2026 consumer trends and industry insights
NewsRomania and Italy, the first ones applying handling fee on parcels below 150 euros from outside the EU. Customs duty comes next

Biopharma M&A rockets to record heights in 2014

15 Jan 2015

Big pharmas, largely absent over the past few years, played a bigger role in 2014’s pyrotechnics, spending nearly US$90 billion on M&A to close — or attempt to close — “growth gaps”.

While big pharmas were mostly focused on creating strategic franchises, specialty pharmas pursued transactions that provided the scale to compete globally. Whatever you thought of specialty pharmas’ actions — destiny made manifest or mere hubris — the resulting fi repower fi reworks, worth more than US$130 billion, were impossible to ignore.

For complete information, please see the attached report, or the Romanian version of the article, here.